reports
- Sean Conroy
Botanix Pharmaceuticals - New dermatological and antimicrobial agents
Botanix Pharmaceuticals is a clinical-stage biotech company focused on the development of novel treatments for common skin conditions. Its approach combines synthetic cannabidiol (CBD) and a patented skin delivery technology, Permetrex, for which Botanix has an exclusive licence in dermatology. After demonstrating encouraging human safety data in Phase I/II, the company has a busy pipeline for 2022, with a Phase IIb antimicrobial trial due to commence in Q122 and a Phase Ib/II trial for rosacea ...
- Sean Conroy
Botanix Pharmaceuticals - New dermatological and antimicrobial agents
Botanix Pharmaceuticals is a clinical-stage biotech company focused on the development of novel treatments for common skin conditions. Its approach combines synthetic cannabidiol (CBD) and a patented skin delivery technology, Permetrex, for which Botanix has an exclusive licence in dermatology. After demonstrating encouraging human safety data in Phase I/II, the company has a busy pipeline for 2022, with a Phase IIb antimicrobial trial due to commence in Q122 and a Phase Ib/II trial for rosacea ...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.